AYX-301 for LAM

TCNP encapsulated red cell therapy for LAM in combination with sirolimus

Tumor cell with red blood cells

Cell Therapy Solution for Respiratory Distress

TCNP encapsulated red cell therapy for LAM in combination with Sirolimus

  • Lymphangioleiomyomatosis (LAM) is a cystic lung disease affecting mainly women of reproductive age.
  • LAM has a prevalence of up to 7.8 per million worldwide. The US LAM registry has ~1400 patients.
  • Sirolimus® is an approved drug; chronic therapy leads to adverse effects, including drug-drug interactions with concomitant medications.
  • AYX-101 as an add-on is a compelling value proposition for superior efficacy and better tolerability.